Cost‐effectiveness of respiratory syncytial virus prophylaxis with palivizumab

CA Reeve, JS Whitehall, PG Buettner… - … of paediatrics and …, 2006 - Wiley Online Library
Background: A monoclonal antibody, palivizumab, directed against respiratory syncytial
virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the …
被引用次数：57 相关文章

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

CA Reeve, JS Whitehall, PG Buettner… - … of Paediatrics & …, 2006 - search.ebscohost.com
Background: A monoclonal antibody, palivizumab, directed against respiratory syncytial
virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the …

[引用][C] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

C Reeve, JS Whitehall… - … of Paediatrics and …, 2006 - researchnow.flinders.edu.au
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab — Research @
Flinders Skip to main navigation Skip to search Skip to main content Research @ Flinders …

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

CA Reeve, JS Whitehall, PG Buettner… - Journal of Paediatrics …, 2006 - europepmc.org
Background A monoclonal antibody, palivizumab, directed against respiratory syncytial virus
(RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost …

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

CA Reeve, JS Whitehall, PG Buettner, R Norton… - 2006 - cabidigitallibrary.org
Background: A monoclonal antibody, palivizumab, directed against respiratory syncytial
virus (RSV) has been shown to decrease hospitalization rates. Because of its expense, the …
[PDF] academia.edu

[PDF][PDF] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

CA Reeve, JS Whitehall, PG Buettner… - Journal of Paediatrics …, 2006 - academia.edu
Background: A monoclonal antibody, palivizumab, directed against respiratory syncytial
virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the …

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

CA Reeve, JS Whitehall… - … of paediatrics and …, 2006 - pubmed.ncbi.nlm.nih.gov
Background A monoclonal antibody, palivizumab, directed against respiratory syncytial virus
(RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost …

[引用][C] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

CA REEVE, JS WHITEHALL, PG BUETTNER… - Journal of paediatrics …, 2006 - Blackwell